ライフサイエンスコーパス: tablet

1 dihydroartemisinin and 40 mg piperaquine per tablet).

2 henytoin in pharmaceutical tables (100mg per tablet).

3 eutical ingredients and excipients of a drug tablet.

4 ribution in various regions of the compacted tablet.

5 ons to millimeters for the macrostrcuture of tablet.

6 thyroid range) while in therapy with L-T4 in tablet.

7 mes can be combined in a single personalised tablet.

8 healthy adults after taking a 1-mg Fluoride tablet.

9 ed in subjects with asthma treated with SLIT-tablet.

10 tion of the amorphous form of the API in the tablet.

11 eplaced by regular doses of oral misoprostol tablets.

12 e recovery towards CPZ in the pharmaceutical tablets.

13 e clinical development of timothy grass SLIT-tablets.

14 loading dose (LD) either as whole or crushed tablets.

15 o the Galaxy system through smart phones and tablets.

16 faecal discolouration) administered as oral tablets.

17 esktops, servers, laptops, smart phones, and tablets.

18 le-stranded RNA adjuvant delivered orally by tablets.

19 f reagents can be encapsulated in compressed tablets.

20 tric formulations as well as fast dissolving tablets.

21 ) for film coating of pharmaceuticals, e.g., tablets.

22 , 4.7%, and 3.8%, respectively, for caffeine tablets.

23 urine samples as well as some pharmaceutical tablets.

24 n the use of caffeinated drinks and caffeine tablets.

25 s to accelerate drug release from 3D printed tablets.

26 ect compression, producing mechanically weak tablets.

27 between the different batches of paracetamol tablets.

28 tanding of the dissolution of pharmaceutical tablets.

29 o group will receive similar-looking placebo tablets.

30 n and adults treated with timothy grass SLIT-tablets.

31 of adulterated extended-release oxymorphone tablets.

32 different assay components into color-coded tablets.

33 d by the quantification of Arg in supplement tablets.

34 er fragmentation during dissolution of these tablets.

35 acebo] to 34% [SQ house dust mite sublingual tablet]).

36 sthma were randomized to a daily SQ HDM SLIT-tablet (12 SQ-HDM dose) or placebo for up to approximate

37 thoxazole in a single fixed-dose combination tablet), 12 weeks of fluconazole, 5 days of azithromycin

38 zole prophylaxis (given as water-dispersible tablets; 120 mg per day for age <6 months, 240 mg per da

39 vir, in a once-daily, fixed-dose combination tablet (134 patients), or sofosbuvir plus weight-based r

40 ok, 2.53 [1.25]; in-person, 2.59 [1.30]; and tablet, 2.34 [1.37]) (F6,674 = 15.60; P < .001; eta2 = 0

41 herapy, 438 patients) or two matched placebo tablets (432 patients) for 12 months.

42 Compared to SelenoPrecise and Se-ACE tablets, a yoghurt-based supplement exhibited a much low

43 e structure analysis deepen understanding of tableting across dimensions from microns to millimeters

44 The SQ HDM SLIT-tablet (ALK) has been developed for treatment of house d

45 d proprietary to the trial sponsor) HDM SLIT-tablet (ALK, Horsholm, Denmark) in adults and adolescent

46 rage, would be greatly improved with an oral tablet alternative made in cell culture.

47 The pharmaceutical tablet analysis measures the sensing with negligible mat

48 ted TRAEs assessed as severe with grass SLIT-tablet and 2/60 with placebo, without a consistent trend

49 are homes, as well as local investigation of tablet and capsule impact on medication administration e

50 l samples; this method was tested in Delmoxa tablet and human urine sample.

51 L161 was better tolerated than the solution; tablet and solution formulations had similar exposures,

52 hose patients currently taking many separate tablets and also allow ready tailoring of a particular d

53 release solid dosage forms, such as the oral tablets and capsules, comprise granular matrices.

54 its capsules twice-daily or matching placebo tablets and capsules.

55 as an active ingredient of direct compressed tablets and film-based delivery carriers.

56 s consumer electronics, such as cell phones, tablets and other portable electronic devices, are typic

57 cost interventions-low-dose oral misoprostol tablets and transcervical Foley catheterisation-are alre

58 women received routine daily iron folic acid tablets and were treated with additional iron folic acid

59 reduced to 83.1% (ACdn-EEX), 90.1% (ACdn-EEX tablet) and 93.8% (ACdn-EEX capsules) after 1 year at 5

60 tasvir (400 mg/100 mg fixed-dose combination tablet) and GS-9857 (100 mg) once daily for 6-12 weeks.

61 ng 20 microg of Phleum p 5 and daily placebo tablets) and 34 received matched double-placebo.

62 % (ACs-EEX), 36.0% (ACs-EES), 64.8% (ACs-EEX tablet), and 71.7% (ACs-EEX capsules) after 1 year at 5

63 non-selenized yeast supplements in capsule, tablet, and liquid forms.

64 material surrounding mature gastropod nacre tablets, and have only once been observed in bivalve nac

65 lacebo] to 5% [SQ house dust mite sublingual tablet]) and an increased probability of having a mild A

66 Given that hydrated matrix tablets are dense multicomponent systems, extended Stefa

67 properties of omega-3 containing powders and tablets are described.

68 ed on video, using an in-built webcam on the tablet as well as an external camera.

69 t prostate cancer were treated with olaparib tablets at a dose of 400 mg twice a day.

70 Patients received alisertib tablets at dose levels of 45, 60, and 80 mg/m(2) per day

71 ectroscopy for the determination of water in tablets, (b) stability study in drug product development

72 s recorded the residents' activities using a tablet-based application.

73 ater social preference as measured using the tablet-based task was associated with increased use of s

74 plus a post-sex dose); or event-driven (one tablet both before and after sex).

75 via several routes: oral tablets, sublingual tablets, buccal tablets, sublingual spray, transdermal o

76 dose (achieved with similar looking placebo tablets), but not allocation up to and including week 48

77 te pressure distribution profiles within the tablet by the deformation of the crystalline particles f

78 Results suggest the ceramic tablet can be used to treat a range of water volumes.

79 xis is rare, and therefore the immunotherapy tablets can be administered at home.

80 and using various formulations of selinexor (tablet, capsule, or suspension).

81 serum TSH levels, and that switching back to tablets caused thyrotropin levels to worsen, leads us to

82 the method of energy input, whilst assessing tablet characteristics of post-milled powders.

83 e once a day (dolutegravir group) or a three-tablet combination of ritonavir-boosted atazanavir plus

84 ect of the SQ grass sublingual immunotherapy tablet compared with placebo on the risk of developing a

85 ask to test social reward preference using a tablet computer (iPad), where two differently coloured b

86 can be transmitted to a nearby smartphone or tablet computer for post-processing, and subsequently to

87 logy Criteria for Adverse Events (CTCAE) via tablet computers at 5 successive clinic visits.

88 They completed PRO-CTCAE items on tablet computers in clinic waiting rooms at 9 US cancer

89 ncer Center to report 12 common symptoms via tablet computers or to receive usual care consisting of

90 In this study, we employed smart tablet computers with touch-sensitive screens and embedd

91 The study regimen consisted of a fixed-dose tablet containing darunavir 800 mg, cobicistat 150 mg, e

92 ssigned (2:1) to receive a once-a-day single-tablet containing elvitegravir 150 mg, cobicistat 150 mg

93 e 12 or 24 weeks of a fixed-dose combination tablet containing ledipasvir and sofosbuvir, once daily,

94 ergic rhinitis were given a daily sublingual tablet containing placebo or STG320 at a dose of 500IR,

95 or 311 days) or Group 2 (1 identical placebo tablet containing starch with no active ingredients ever

96 d 2 years of sublingual immunotherapy (daily tablets containing 15 microg of major allergen Phleum p

97 ly assigned (1:1) to receive once-daily oral tablets containing 150 mg elvitegravir, 150 mg cobicista

98 In this work tablets containing 25-40% (w/w) omega-3 oil as triglycer

99 The aim of this study with tablets containing carbamylated monomeric house dust mit

100 plates and can detect them from multivitamin tablets, corn flakes, energy drinks, cerebrospinal fluid

101 supplementation was 87%, assessed by monthly tablet counts.

102 Compared with whole tablets, crushed prasugrel led to reduced P2Y12 reaction

103 Patients took safinamide or placebo as 1 tablet daily with breakfast.

104 dings show the safety and efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofov

105 ean study drug consumption was 0.41 and 0.91 tablets/day, respectively.

106 on for up to 7 days, followed by twice-daily tablets delivering 5.5 mg/kg per day for 12 weeks).

107 ssment of the CSF that were implemented on a tablet device.

108 ned from consecutive patients with ALS using tablet devices in waiting rooms (Knowledge Program).

109 reen-based media device (eg, cell phones and tablet devices) access or use in the sleep environment a

110 tableting technology, we show the ability of tableted diagnostics for screening hepatitis B-positive

111 asthma included in these studies, grass SLIT-tablet did not increase TEAE frequency, severe local all

112 treatment with placebo (n = 277) or HDM SLIT tablet (dosage groups: 6 SQ-HDM [n = 275] or 12 SQ-HDM [

113 excipient employed in orally disintegrating tablets due to its high palatability.

114 at a dose of 150 mg daily) or daily placebo tablets during and after radiation therapy.

115 n reported not consuming the iron folic acid tablets during pregnancy.

116 d combined artemether and lumefantrine (four tablets, each containing 20 mg artemether and 120 mg lum

117 HDM SLIT-tablet effects were numerically greater than all pharmac

118 were randomly assigned to Group 1 (1 TMP-SMZ tablet every 2 days for 311 days) or Group 2 (1 identica

119 ants were instructed to take 1 or 2 of these tablets every 8 hours, as needed for LBP.

120 ents who were allocated eltrombopag received tablets (except for those aged 1-5 years who received an

121 ion plus once-daily dapagliflozin 10 mg oral tablets, exenatide with dapagliflozin-matched oral place

122 harmacokinetics, and efficacy of this single-tablet, fixed-dose combination of elvitegravir, cobicist

123 The single-tablet, fixed-dose combination of elvitegravir, cobicist

124 dardised quality) house dust mite sublingual tablet for 1 year resulted in a decreased probability of

125 n B-12 or a matching placebo as a daily oral tablet for 12 mo.

126 first North American trial of use of a SLIT-tablet for HDM allergy, 12 SQ-HDM was well tolerated and

127 65-year-old female whom took lactate calcium tablets for 5 years presented with progressive dysphagia

128 of coffee, caffeinated drinks, and caffeine tablets for CE and potential factors derived from profes

129 In all patients who received L-T4 in tablet form after switching to an oral liquid formulatio

130 ment strategies of iodine supplementation in tablet form with no iodine supplementation for pregnant

131 al gefitinib 250 mg or placebo once daily in tablet form; randomisation did not include stratificatio

132 s an opioid antagonist which as a once-a-day tablet formulation has recently been approved for reduci

133 The tablet formulation of LCL161 was better tolerated than t

134 a BRCA1 or BRCA2 (BRCA1/2) mutation using a tablet formulation of olaparib.

135 lly administered via a radiolabelled osmotic tablet formulation.

136 Purpose Fentanyl sublingual tablets (FST) are a potentially useful alternative to pa

137 ted MSM requiring 3-drug PEP received single-tablet FTC-RPV-TDF once daily for 28 days.

138 of caffeine in real samples (urine, plasma, tablet, green tea, energy and soda drink).

139 Asthma onset was less frequent in SLIT tablet group than in non-AIT group (odds ratio: 0.696, P

140 relative to the pretreatment period) in SLIT tablet group than in the non-AIT group (P<.001).

141 tive to the pretreatment period) in the SLIT tablet group vs the non-AIT group (P=.004).

142 This was shown through higher tablet hardness and increased plastic deformation profil

143 SQ house dust mite sublingual immunotherapy tablets has been demonstrated in patients with allergic

144 Crushing tablets has been suggested to lead to more favorable PK/

145 However, the niche omega-3 tablets have so far remained unexplored.

146 a software application running on a computer tablet, housed in a bespoke viewing chamber.

147 The map of deformation degrees within the tablet illustrated the heterogeneous pressure distributi

148 d the efficacy and safety of the SQ HDM SLIT-tablet in adults with moderate-to-severe HDM-induced all

149 Using data from eight trials of grass SLIT-tablet in subjects with allergic rhinitis with/without c

150 ake of 85% or more of the required number of tablets in 79.9% of the participants.

151 grass pollen sublingual immunotherapy (SLIT) tablets in AR and their impact on asthma onset and progr

152 al to assess the efficacy/safety of HDM SLIT-tablets in North American subjects with HDM-induced alle

153 telet inhibitory effects compared with whole tablets in STEMI patients undergoing PPCI.

154 e efficacy of these sublingual immunotherapy tablets in the treatment of allergic rhinitis has been f

155 ent antiplatelet effects compared with whole tablet ingestion.

156 assess the safety and efficacy of the single tablet integrase inhibitor regimen containing elvitegrav

157 For vitamin C tablets, inter- and intra-day precisions were 0.4% and 0

158 ility of nacre can be limited by eliminating tablet interactions during crack propagations.

159 to time-dependent boundary conditions at the tablet interface.

160 exhibit complete brittle fracture along the tablet interfaces at the proportional limit under pure s

161 DM) sublingual allergen immunotherapy (SLIT) tablet is a potential novel treatment option for HDM all

162 tial resolution to resolve microparticles in tablets is essential to ensure high quality and efficacy

163 Sublingual administration of rBet v 1 tablets is safe and efficacious in patients with BP alle

164 g 2000 UA/day monomeric allergoid sublingual tablets is well tolerated and reduces the CPT reaction i

165 sites, as compared to the commercial LPV/RTV tablet (Kaletra(R)) in rats.

166 l activity of these clinically effective TIM tablets led in the same range (6200-8200 BAU; 0.92-1.23

167 and alignment (parallel or at right angle to tablet long axis).

168 Herein, we developed a sublingual tablet made of pharmaceutical-grade recombinant Bet v 1.

169 were switched back again to receive L-T4 in tablets, maintaining the dosage, TSH levels worsened aga

170 controlled, phase 3 trial evaluated olaparib tablet maintenance treatment in platinum-sensitive, rela

171 INTERPRETATION: Olaparib tablet maintenance treatment provided a significant prog

172 However, the use of FDM 3D printing in tablet manufacturing requires a large portion of polymer

173 ady-to-use inactivated yeast interfering RNA tablets may one day facilitate the seamless integration

174 cline of chemical potential gradients at the tablet-medium interface that drive drug release.

175 cebo-controlled trials of Timothy grass SLIT-tablet MK-7243 (2800 BAU/75 000 SQ-T, Merck/ALK-Abello)

176 f action of the HDM sublingual immunotherapy tablet MK-8237 (Merck/ALK-Abello) using the Vienna Chall

177 t mite (HDM) sublingual immunotherapy (SLIT) tablet (MK-8237; Merck & Co, Kenilworth, NJ/ALK-Abello,

178 Two 20-mg prednisolone tablets (n = 199) or matched placebo (n = 202) once dail

179 D3 (2400 IU/d; n = 315) or matching placebo tablets (n = 308) from pregnancy week 24 to 1 week postp

180 (VACV) 2 g thrice daily (n = 40) or placebo tablets (n = 47) for 90 days (12 tablets of study medica

181 1.19]; in-person [n = 165], 2.66 [1.11]; and tablet [n = 71], 2.53 [1.17]) and at 12 months (workbook

182 Of all the opioid tablets obtained by surgical patients, 42% to 71% went u

183 ents aged 12-17 years received a combination tablet of 90 mg ledipasvir and 400 mg sofosbuvir once da

184 Patients were given a fixed-dose combination tablet of 90 mg ledipasvir and 400 mg sofosbuvir orally

185 perienced) received a fixed-dose combination tablet of 90 mg of ledipasvir and 400 mg of sofosbuvir o

186 The fixed-dose combination dispersible tablet of arterolane maleate (AM) 37.5 mg and piperaquin

187 One tablet of ferrous gluconate (37.5 mg of elemental iron)

188 patients received the fixed-dose combination tablet of LDV-SOF once-daily plus weight-based RBV (1,00

189 igned to groups given fixed-dose combination tablet of ledipasvir and sofosbuvir (n = 25) or ledipasv

190 The first received a fixed-dose combination tablet of ledipasvir-sofosbuvir (90/400 mg) once daily f

191 t with the once-daily fixed-dose combination tablet of ledipasvir/sofosbuvir (LDV/SOF) with and witho

192 The tablet of multi-unit pellet system (TMUPS), using coated

193 eive treatment with a fixed-dose combination tablet of sofosbuvir-velpatasvir-voxilaprevir with or wi

194 All volunteers were treated with 1 tablet of TMP-SMZ (160 mg/800 mg) twice daily for 45 day

195 ollowed by once daily combination fixed-dose tablets of 90 mg ledipasvir and 400 mg sofosbuvir plus w

196 fter unintentional ingestion of three 500 mg tablets of Closantel.

197 ptor agonist for 6-12 months and once-weekly tablets of dipeptidyl peptidase-4 inhibitors.

198 espectively, can be directly compressed into tablets of excellent quality.

199 of treatment with 500IR and 300IR sublingual tablets of HDM allergen extracts was efficacious and wel

200 In a natural field study, sublingual tablets of house dust mite (HDM) allergen extracts (STG3

201 All participants were given 20 tablets of naproxen, 500 mg, to be taken twice a day.

202 They were randomized to receive either 60 tablets of placebo; cyclobenzaprine, 5 mg; or oxycodone,

203 or placebo tablets (n = 47) for 90 days (12 tablets of study medication daily).

204 in which participants were given combination tablets of tenofovir disoproxil fumarate (300 mg) and em

205 SLIT-tablets offer the additional benefit of long-term effica

206 s elbasvir 50 mg in a fixed-dose combination tablet once daily for 12 weeks.

207 sofosbuvir (400 mg) as a single combination tablet once per day.

208 ed solid, orally administered medications in tablet or capsule form at ten purposively sampled care h

209 svir in a once-daily, fixed-dose combination tablet or matching placebo for 12 weeks.

210 ate the phytochemical content in 10 samples (tablets or capsules), showing concentrations of (+)-cate

211 articipants received oral cabotegravir 30 mg tablets or matching placebo once daily during a 4 week o

212 ups receiving either SCIT injections or SLIT tablets or neither.

213 :1) to receive either eltrombopag or placebo tablets (or oral suspension formulation if aged 1-5 year

214 nts received sublingual immunotherapy (SLIT) tablet (Oralair, Stallergenes(c)) and symptomatic therap

215 orally once daily or raltegravir 400 mg (one tablet) orally twice daily, each with tenofovir disoprox

216 se system to raltegravir 1200 mg (two 600 mg tablets) orally once daily or raltegravir 400 mg (one ta

217 cacy and safety of 2 doses of HDM sublingual tablets over 1 treatment year and the subsequent immunot

218 Tmax was shorter with crushed vs whole tablets (P = .047).

219 families, 23 expressed a preference for the tablet PC over the notebook, 3 had no preference, and 4

220 We have developed a tablet PC-based solution that provides secure and nearly

221 ference, and 4 preferred the notebook to the tablet PC.

222 tricitabine (200 mg) and advised to take one tablet per day.

223 motherapy still had doses equivalent to five tablets per day of 5-mg hydrocodone.

224 c opioid users ( P = .05), equivalent to six tablets per day of 5-mg hydrocodone.

225 use of at least 0.5 to 1.5 standard aspirin tablets per week; the minimum duration of regular use as

226 patients received an electronic interactive tablet personal computer intervention.

227 sofosbuvir (400 mg) once daily (combination tablet), plus ribavirin (600-1200 mg daily).

228 in powder blends in the feed frame (FF) of a tablet press.

229 ecause of the much higher production rate of tableting process.

230 Despite its long-term application in tablet production, effects of zein coating on tablet pro

231 The use of Apps running on smartphones and tablets profoundly affects medicine.

232 ablet production, effects of zein coating on tablet properties are still not fully understood.

233 ol fragmentation and provide improvements in tablet properties.

234 t with the SQ grass sublingual immunotherapy tablet reduced the risk of experiencing asthma symptoms

235 han 50% of the expected number of vismodegib tablets; reduction in the number of surgical excisions r

236 y, and tolerability of switching to a single-tablet regimen containing rilpivirine, emtricitabine, an

237 isoproxil fumarate (TDF) as a 3-drug, single-tablet regimen for PEP in men who have sex with men (MSM

238 No once-daily single-tablet regimen is available for HIV-infected children un

239 efficacy and safety of switching to a single-tablet regimen of darunavir, cobicistat, emtricitabine,

240 ly assigned (1:1) to receive either a single-tablet regimen of dolutegravir plus abacavir and lamivud

241 alafenamide (25 mg) or to continue a single-tablet regimen of efavirenz (600 mg), emtricitabine (200

242 randomly assigned (1:1) to receive a single-tablet regimen of either rilpivirine (25 mg), emtricitab

243 A single-tablet regimen of FTC-RPV-TDF was well tolerated as once

244 randomly assigned (1:1) to receive a single-tablet regimen of rilpivirine (25 mg), emtricitabine (20

245 alafenamide (25 mg) or to remain on a single-tablet regimen of rilpivirine (25 mg), emtricitabine (20

246 In the phase 3 ION program, the single-tablet regimen of the NS5A inhibitor ledipasvir and NS5B

247 Participants received a single-tablet regimen once per day with food (administered by t

248 usehold water storage container, the ceramic tablet releases silver ions at a controlled rate that in

249 patients and investigate IV exposure to the tablet's inert ingredients as a possible causal mechanis

250 to tap the peak of a "sweep grating" on the tablet's touch screen.

251 P and INH in human serum, urine, saliva, and tablet samples.

252 ay diffractograms of the powders and crushed tablets show evidence of the formation of new crystallin

253 Analysis of the formed tablets showed the drug to be evenly distributed within

254 t with the SQ grass sublingual immunotherapy tablet significantly reduced the risk of experiencing as

255 We quantitatively separate the initial tablet sliding primarily resisted by nanoscale aragonite

256 e events (AEs) with sublingual immunotherapy tablet (SLIT-tablet) treatment, such as severe systemic

257 We show that tableting stabilizes heat-sensitive reagents and simplif

258 es: oral tablets, sublingual tablets, buccal tablets, sublingual spray, transdermal ointment, and tra

259 ations for delivery via several routes: oral tablets, sublingual tablets, buccal tablets, sublingual

260 variety of delivery vehicles in addition to tablets, such as medical devices for example.

261 to follow crystallization of indomethacin on tablet surfaces under two storage conditions: 30 degrees

262 solid-state forms and their changes on drug tablet surfaces.

263 To test the clinical readiness of this tableting technology, we show the ability of tableted di

264 In seasonal allergy trials with grass SLIT-tablet, the observed treatment effect is highly dependen

265 pepsin and amino acid hydrochloride taken as tablets three times daily for 6 weeks.

266 mine the biological activity of solution and tablet Timothy grass pollen (TIM) extracts, compared to

267 The video was shown on a tablet to children in the experimental group the afterno

268 The fact that the change from tablets to liquid oral formulation normalised serum TSH

269 ) with sublingual immunotherapy tablet (SLIT-tablet) treatment, such as severe systemic reactions and

270 of treatment in 2 house dust mite (HDM) SLIT-tablet trials (n = 1768).

271 ntire pollen seasons in 6 timothy grass SLIT-tablet trials (n = 3094) and 2 ragweed SLIT-tablet trial

272 -tablet trials (n = 3094) and 2 ragweed SLIT-tablet trials (n = 658) and during the last 8 weeks of t

273 SLIT-tablet trials allowed rescue medication use, whereas mos

274 eneity and use of rescue medications in SLIT-tablet trials, effects on nasal symptoms with timothy gr

275 In grass and ragweed SLIT-tablet trials, overall improvement in TNSSs relative to

276 In HDM SLIT-tablet trials, TNSS overall improvement relative to plac

277 1,500 mg every 4 weeks with either olaparib tablets twice daily or cediranib on two schedules.

278 were randomly assigned to simvastatin 20 mg tablets twice-daily plus vitamin D3 1,000 international

279 ive extended-pulsed fidaxomicin (200 mg oral tablets, twice daily on days 1-5, then once daily on alt

280 signed 2:1 to olaparib (300 mg in two 150 mg tablets, twice daily) or matching placebo tablets using

281 mg tablets, twice daily) or matching placebo tablets using an interactive voice and web response syst

282 hes of analgesic paracetamol (acetaminophen) tablets using nitrogen-14 nuclear quadrupole resonance s

283 ess the safety and immunogenicity of an oral tablet vaccine against influenza A H1N1 in healthy adult

284 children with asthma treated with grass SLIT-tablet versus subjects without asthma in or outside of p

285 atment of AR patients with grass pollen SLIT tablets was associated with slower AR progression, less

286 The treatment effect of timothy grass SLIT-tablets was considered similar between pediatric (n = 79

287 icacy of rBet v 1 formulated as a sublingual tablet were assessed in a multicentre, double-blind, pla

288 , AR patients treated with grass pollen SLIT tablets were compared with a control group not having re

289 Primaquine tablets were dissolved into a solution and administered

290 symptoms with timothy grass and ragweed SLIT-tablets were nearly as great as with MFNS and numericall

291 of the hydrophilic plane, whilst more robust tablets were produced.

292 Disintegration times of post-milled tablets were reduced due to the exposure of the hydrophi

293 Aripiprazole or placebo tablets were started at 2 mg daily and titrated as toler

294 Bet v 1 tablets were well tolerated by patients, consistent with

295 The SBS2 system consists of an Android tablet wirelessly connected to a 14-electrode EasyCap he

296 Tablets with bespoke geometries (honeycomb architecture)

297 or triple fixed-dose-combination paediatric tablets with lamivudine and nevirapine or efavirenz.

298 nt effect of sublingual immunotherapy (SLIT)-tablets with pharmacotherapy for seasonal allergic rhini

299 s receiving once daily for 5 months rBet v 1 tablets, with a mean difference of 17.0-17.7% relative t

300 o investigate the effects of Xueshuan Xinmai tablets (XXMT) on neurologic deficits, quality of life a